In the emerging field of MRI in prostate cancer (PCa) diagnosis, it has become clear that targeted biopsy with MRI guidance has additional value over systematic transrectal ultrasound-guided biopsies (TRUS-Bx) alone. The targeted biopsy approach driven by a positive MRI increases the diagnostic yield of high-grade [Gleason score (GS) ≥3+4] or clinically significant (cs) PCa, while concomitantly reducing the number of biopsy cores and the detection of low-grade PCa (GS 3+3) (1-3). Consequently, the question arises what the diagnostic accuracy of MRI (with or without targeted biopsies) in current clinical practice would be?

Additional Metadata
Persistent URL,
Journal Translational Andrology and Urology
Schoots, I.G, & Roobol-Bouts, M.J. (2017). From PROMIS to PRO-MRI in primary prostate cancer diagnosis. Translational Andrology and Urology, 6(3), 604–607. doi:10.21037/tau.2017.04.35